View Item 

Show simple item record

New treatment paradigm for hemophilia poses challenges for legacy bioassays
dc.contributor.authorPipe, Steven W.
dc.date.accessioned2019-09-30T15:32:08Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2019-09-30T15:32:08Z
dc.date.issued2019-09
dc.identifier.citationPipe, Steven W. (2019). "New treatment paradigm for hemophilia poses challenges for legacy bioassays." Journal of Thrombosis and Haemostasis 17(9): 1446-1448.
dc.identifier.issn1538-7933
dc.identifier.issn1538-7836
dc.identifier.urihttps://hdl.handle.net/2027.42/151338
dc.publisherWiley Periodicals, Inc.
dc.titleNew treatment paradigm for hemophilia poses challenges for legacy bioassays
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151338/1/jth14550_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151338/2/jth14550.pdf
dc.identifier.doi10.1111/jth.14550
dc.identifier.sourceJournal of Thrombosis and Haemostasis
dc.identifier.citedreferencePipe SW. Bioengineered molecules for the management of haemophilia: promise and remaining challenges. Haemophilia. 2018; 24 ( Suppl 6 ): 68 – 75.
dc.identifier.citedreferenceBulla O, Poncet A, Alberio L, Asmis LM, Gahler A, Graf L, et al. Impact of a product‐specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study. Haemophilia. 2017; 23: e335 – 9.
dc.identifier.citedreferenceIngerslev J, Jankowski MA, Weston SB, Charles LA; ReFacto Field Study Participants. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr factor VIII: C activity in hemophilic plasma using one‐stage clotting assays. J Thromb Haemost. 2004; 2: 623 – 8.
dc.identifier.citedreferenceTeichman J, Chaudhry HR, Sholzberg M. Novel assays in the coagulation laboratory: a clinical and laboratory perspective. Transfus Apher Sci. 2018; 57: 480 – 4.
dc.identifier.citedreferenceKitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012; 18: 1570 – 4.
dc.identifier.citedreferenceOldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017; 377: 809 – 18.
dc.identifier.citedreferenceYoneyama K, Schmitt C, Kotani N, Levy GG, Kasai R, Iida S, et al. A pharmacometric approach to substitute for a conventional dose‐finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A. Clin Pharmacokinet. 2018; 57: 1123 – 34.
dc.identifier.citedreferenceMahlangu J, Oldenburg J, Paz‐Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018; 379: 811 – 22.
dc.identifier.citedreferenceShima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. Long‐term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017; 1: 1891 – 9.
dc.identifier.citedreferenceUchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S, et al. A first‐in‐human phase 1 study of ACE910, a novel factor VIII‐mimetic bispecific antibody, in healthy subjects. Blood. 2016; 127: 1633 – 41.
dc.identifier.citedreferenceLeksa NC, Aleman MM, Goodman A, Rabinovich D, Peters R, Salas J. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence. J Thromb Haemost. 2019; 17: 1044 – 1052.
dc.identifier.citedreferenceLenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017; 130: 2463 – 8.
dc.identifier.citedreferenceRecommendation on the Use and Management of Emicizumab‐kzwh (Hemlibra) for Hemophilia A with and without Inhibitors. Medical and Scientific Advisory Council (MASAC) to the National Hemophilia Foundation, 2019.
dc.identifier.citedreferenceMiller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, et al.; Hemophilia Inhibitor Research Study Investigators. Comparison of clot‐based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost. 2013; 11: 1300 – 9.
dc.identifier.citedreferenceDuncan E, Rodgers S. One‐stage factor VIII assays. Methods Mol Biol. 2017; 1646: 247 – 63.
dc.identifier.citedreferencePeyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one‐stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016; 14: 248 – 61.
dc.identifier.citedreferenceTurecek PL, Romeder‐Finger S, Apostol C, Bauer A, Crocker‐Buque A, Burger DA, et al. A world‐wide survey and field study in clinical haemostasis laboratories to evaluate FVIII: C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia. 2016; 22: 957 – 65.
dc.identifier.citedreferenceCollins P, Chalmers E, Chowdary P, Keeling D, Mathias M, O’Donnell J, et al. The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016; 22: 487 – 98.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jth14550_am.pdf
Size:
137.8KB
Format:
PDF
View/Open
Name:
jth14550.pdf
Size:
271.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.